check_circleStudy Completed

Prostatic Neoplasms

Second primary cancers in patients with castration resistant prostate cancer

Trial purpose

This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated with radium-223-dichloride.

Key Participants Requirements

Sex

Male

Age

18 - N/A

Trial summary

Enrollment Goal
6442
Trial Dates
March 2016 - October 2017
Phase
N/A
Could I Receive a placebo
No
Products
Unspecified
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, Germany

Primary Outcome

  • Incidences of Second primary malignancies are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.
    date_rangeTime Frame:
    Up to 10 years
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Overall survival
    date_rangeTime Frame:
    Up to 10 years
    enhanced_encryption
    Safety Issue:
    No

Trial design

Second primary cancers in patients with castration resistant prostate cancer (BOCARP)
Trial Type
Observational
Intervention Type
Other
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A